Across TCGA pan-cancer cohorts, MIR4462 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of MIR4462’s most consistent transcriptional readouts.
The strongest signal is observed in thyroid carcinoma (THCA), where MIR4462 RNA is repressed in tumor relative to normal tissue. In most cancer types MIR4462 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.
THCA and LUAD are the cancer types where MIR4462 tumor–normal differential expression is most reproducible.